{
  "run_date": "2026-02-08T17:14:07.243033+00:00",
  "stocks_scanned": 235,
  "top_picks": [
    {
      "ticker": "TKA",
      "name": "thyssenkrupp AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 11.655,
      "currency": "EUR",
      "market_cap": 9659455488,
      "pe_ratio": 15.54,
      "forward_pe": 10.92704,
      "roe": 5.0869998,
      "dividend_yield": 129.0,
      "momentum_6m": 19.602403566203286,
      "momentum_12m": 157.50894348275168,
      "rsi_14": 66.40772694967322,
      "alpha_score": 82,
      "score_breakdown": {
        "value": 21,
        "quality": 15,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 8
      },
      "yahoo_url": "https://finance.yahoo.com/quote/TKA.DE",
      "signal": "BUY",
      "confidence": "MEDIUM",
      "reasoning": "thyssenkrupp AG is a German industrial conglomerate operating in materials, industrial solutions, and marine systems. The company has undergone significant financial restructuring, reducing its debt-to-equity ratio from 57.5% to 2.4% over the past five years while maintaining \u20ac5.74B in cash reserves against only \u20ac253M in debt.[1] The stock has demonstrated exceptional momentum, with a 157.5% return over the past 12 months, though this follows a period of transformation and strategic repositioning in a challenging macroeconomic environment.[2]",
      "company_overview": "thyssenkrupp AG is a German industrial conglomerate operating in materials, industrial solutions, and marine systems. The company has undergone significant financial restructuring, reducing its debt-to-equity ratio from 57.5% to 2.4% over the past five years while maintaining \u20ac5.74B in cash reserves against only \u20ac253M in debt.[1] The stock has demonstrated exceptional momentum, with a 157.5% return over the past 12 months, though this follows a period of transformation and strategic repositioning in a challenging macroeconomic environment.[2]",
      "key_developments": [
        "**Earnings growth acceleration**: thyssenkrupp has been growing earnings at an average annual rate of 26%, significantly outpacing the Metals and Mining industry average of 2.3% annually.[5]"
      ],
      "catalysts": [
        "**Q1 2025/2026 interim report and analyst call** (February 12, 2026): Critical earnings update that will signal whether the 26% earnings growth trajectory continues and provide guidance on execution of transformation initiatives."
      ],
      "risk_factors": [
        "**Execution risk on green steel transition**: High capital requirements and potential delays in commercializing green steel technology could pressure profitability and cash flow despite market optimism.[1]"
      ],
      "sources": [
        "https://simplywall.st/stocks/de/materials/etr-tka/thyssenkrupp-shares/health",
        "https://www.thyssenkrupp.com/en/investors",
        "https://www.thyssenkrupp.com/en/investors/reporting-and-publications",
        "https://www.marketscreener.com/quote/stock/THYSSENKRUPP-AG-436698/finances/",
        "https://simplywall.st/stocks/de/materials/etr-tka/thyssenkrupp-shares/past",
        "https://eulerpool.com/en/stock/thyssenkrupp-Stock-DE0007500001/NetIncome"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "EN",
      "name": "Bouygues SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 48.25,
      "currency": "EUR",
      "market_cap": 18544437248,
      "pe_ratio": 17.545454,
      "forward_pe": 13.719469,
      "roe": 8.397,
      "dividend_yield": 415.00000000000006,
      "momentum_6m": 25.84767816372373,
      "momentum_12m": 60.73101046194995,
      "rsi_14": 69.28839450740628,
      "alpha_score": 78,
      "score_breakdown": {
        "value": 21,
        "quality": 9,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/EN.PA",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Bouygues demonstrates resilient performance with consistent sales growth across quarters, a confirmed positive full-year 2025 outlook, and attractive valuation metrics including a forward P/E of 11.76 and high dividend yield, supported by momentum from +60.7% 12-month returns.[1][2][3] Technical indicators point to further short-term upside in a low-risk profile, though tempered by recent profit declines and macroeconomic uncertainties.[1][2] In a stabilizing European industrials context, the company's diversification and construction strength position it for outperformance.",
      "company_overview": "Bouygues SA is a diversified French conglomerate operating in construction, telecommunications, and media, with a market capitalization of approximately \u20ac15.19 billion and trailing twelve-month revenue of \u20ac57.16 billion.[2] The company holds a solid position in European industrials, evidenced by strong 2024 financials showing revenue up 1.32% to \u20ac56.80 billion and net income up 1.73% to \u20ac1.06 billion, alongside robust stock performance with a 52-week high of \u20ac48.25 and a dividend yield of 5.02%.[2] As of early February 2026, shares trade at \u20ac48.25 with a P/E of 14.49, reflecting steady growth amid a low-beta (0.68) profile.[2][3]",
      "key_developments": [
        "Released nine-month 2025 results on November 5, 2025, showing sales up 0.9% year-on-year but profit down, while maintaining full-year 2025 outlook for slight increases in current operating profit (COPA) and sales at constant exchange rates.[2]",
        "Reported strong construction sales and financial resilience in the nine-month 2025 earnings call, despite challenges, with first-half 2025 sales up 1.3% to \u20ac26.9 billion and Q1 2025 sales up 2.2% to \u20ac12.6 billion, confirming 2025 group outlook.[2]",
        "Monthly share disclosure on February 2, 2026, confirming 385,439,418 total shares and 496,550,003 exercisable voting rights as of January 31, 2026, indicating stable capital structure.[4]",
        "Stock gained 0.364% to $11.02 (OTC equivalent) on February 3, 2026, within a weak short-term rising trend signaling potential 5.92% upside over three months.[1]"
      ],
      "catalysts": [
        "Q4 and full-year 2025 earnings release on February 26, 2026, potentially confirming outlook beats and providing 2026 guidance.[2]",
        "Potential dividend payment momentum following May 5, 2025 ex-date, with 5.02% yield drawing income investors.[2]"
      ],
      "risk_factors": [
        "Declining nine-month 2025 profits despite sales growth, signaling margin pressures in a uncertain macroeconomic and geopolitical environment.[2]",
        "Short-term technical divergences like falling volume on price rises and MACD sell signals, increasing volatility risk near support levels around \u20ac46-47.[1][3]"
      ],
      "sources": [
        "https://stockinvest.us/stock/BOUYY",
        "https://stockanalysis.com/quote/epa/EN/",
        "https://www.investing.com/equities/bouygues",
        "https://www.globenewswire.com/news-release/2026/02/02/3230458/0/en/bouygues-monthly-disclosure-of-the-total-number-of-shares-and-voting-rights.html"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "AZN",
      "name": "AstraZeneca PLC",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 14104.0,
      "currency": "GBP",
      "market_cap": 218651983872,
      "pe_ratio": 31.623316,
      "forward_pe": 18.560966,
      "roe": 21.674,
      "dividend_yield": 173.0,
      "momentum_6m": 27.799927509967382,
      "momentum_12m": 20.387470630408732,
      "rsi_14": 54.043839758125465,
      "alpha_score": 75,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AZN.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "AstraZeneca is a British-Swedish multinational pharmaceutical company that has successfully transformed from a traditional \"pill-mill\" business into a high-growth oncology and rare disease powerhouse[2]. The company has navigated a major patent cliff through strategic acquisitions (notably Alexion) and now generates $58.6 billion in annual revenue with core EPS of $9.12, supported by a robust pipeline in antibody-drug conjugates (ADCs) and other advanced therapeutics[2]. With a market capitalization of $596.31 billion, AstraZeneca is trading at elevated valuations but backed by strong operational momentum and institutional support[1][2].",
      "company_overview": "AstraZeneca is a British-Swedish multinational pharmaceutical company that has successfully transformed from a traditional \"pill-mill\" business into a high-growth oncology and rare disease powerhouse[2]. The company has navigated a major patent cliff through strategic acquisitions (notably Alexion) and now generates $58.6 billion in annual revenue with core EPS of $9.12, supported by a robust pipeline in antibody-drug conjugates (ADCs) and other advanced therapeutics[2]. With a market capitalization of $596.31 billion, AstraZeneca is trading at elevated valuations but backed by strong operational momentum and institutional support[1][2].",
      "key_developments": [
        "**Stock surge to new highs**: AstraZeneca reached a 52-week high of $191.43 on the NASDAQ in early February 2026, more than doubling from a prior close of $92.77, driven by heavy trading volume and positive market sentiment[1]."
      ],
      "catalysts": [
        "**Late-2026 data readouts**: Results for Camizestrant (breast cancer) and Baxdrostat (hypertension) could unlock billions in new peak sales[2]."
      ],
      "risk_factors": [
        "**Farxiga patent cliff**: The blockbuster Farxiga faces its first major generic entries in 2026 across several global markets, requiring rapid pipeline scaling to offset revenue loss[2]."
      ],
      "sources": [
        "https://www.marketbeat.com/instant-alerts/astrazeneca-nasdaqazn-sets-new-12-month-high-should-you-buy-2026-02-02/",
        "http://markets.chroniclejournal.com/chroniclejournal/article/finterra-2026-2-6-the-phoenix-of-big-pharma-a-2026-deep-dive-into-astrazenecas-global-dominance",
        "https://www.stocktitan.net/sec-filings/AZN/6-k-astrazeneca-plc-current-report-foreign-issuer-5cf8521c5fa8.html"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "FERG",
      "name": "Ferguson Enterprises Inc.",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Industrials",
      "price": 19170.0,
      "currency": "GBP",
      "market_cap": 38471598080,
      "pe_ratio": 26.260273,
      "forward_pe": 23.096275,
      "roe": 33.404,
      "dividend_yield": 138.0,
      "momentum_6m": 16.616244059754326,
      "momentum_12m": 31.685590830856224,
      "rsi_14": 64.28571428571428,
      "alpha_score": 71,
      "score_breakdown": {
        "value": 9,
        "quality": 22,
        "momentum": 25,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/FERG.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Ferguson's Q1 results demonstrate resilient execution with margin expansion, non-residential tailwinds (e.g., data centers), and disciplined capital allocation amid housing weakness.[1][2][3][4] Updated guidance signals confidence in 5% growth and margin gains for CY2025, aligning with strong metrics (P/E 26.3, ROE 33.4%, momentum score 25/100).[user query][2][3] High shareholder returns and low leverage position it well for market recovery.",
      "company_overview": "Ferguson Enterprises Inc. (FERG) is a leading distributor of plumbing, HVAC, appliances, and related products primarily in the U.S., with a strong focus on non-residential markets like data centers and waterworks.[1][3][4] The company reported robust Q1 2026 results (quarter ended October 31, 2025), with net sales up 5.1% YoY to $8.2 billion, gross margins expanding 60 bps to 30.7%, and adjusted operating profit rising 14.4% to $808 million, driven by non-residential strength despite residential weakness.[1][2][3][4][8] Shares have delivered strong returns (+31.7% over 12 months), supported by high ROE (33.4%) and ongoing shareholder returns.[user query]",
      "key_developments": [
        "Q1 2026 earnings released December 9, 2025: Revenue $8.17-8.2B (+5.1% YoY, slightly below some estimates), EPS $2.84-$2.90 (beat consensus of $2.62-$2.77), with margin expansion and $372M returned to shareholders via dividends (up 7% to $0.89/share) and repurchases.[1][2][3][4][5][8]",
        "Strategic acquisition of Moore Supply Company to bolster HVAC in Chicago; non-residential revenue grew 12% (led by 21% in commercial mechanical from data centers), offsetting 1% residential decline.[2][3][4]",
        "Updated FY2025 guidance: ~5% revenue growth, operating margins 9.4-9.6% (improved from prior), CapEx ~$350M; strong balance sheet with net debt/EBITDA at 1.1x.[2][3]"
      ],
      "catalysts": [
        "Q2 2026 earnings (expected ~March 2026), with potential for continued non-residential outperformance and margin beats.[3][6]",
        "Progress on large projects (data centers >50% of capex revenue) and acquisitions driving organic + inorganic growth.[2][4]"
      ],
      "risk_factors": [
        "Persistent residential weakness from soft housing starts, permits, and RMI activity, potentially pressuring ~50% of U.S. revenue.[4]",
        "EPS miss vs. some higher estimates ($2.97) led to initial 3% stock drop; broader market uncertainty in industrials could amplify volatility.[4]"
      ],
      "sources": [
        "https://www.quiverquant.com/news/Ferguson+Enterprises+(FERG)+Earnings:+Q1+2026+EPS+Beats+as+Profits+Rise",
        "https://www.moomoo.com/news/post/62629271/ferguson-enterprises-inc-ferg-q1-2026-earnings-call-transcript-summary",
        "https://quartr.com/companies/ferguson-enterprises-inc_3672",
        "https://www.youtube.com/watch?v=ZKruzocZHyc",
        "https://www.marketbeat.com/stocks/NYSE/FERG/earnings/",
        "https://www.corporate.ferguson.com/investor/events-results-and-reports/default.aspx",
        "https://www.corporate.ferguson.com/investor/why-ferguson/default.aspx",
        "https://www.corporate.ferguson.com/pressroom/news-releases/news-details/2025/Ferguson-Reports-Quarter-Ended-October-31-2025/default.aspx"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "ENR",
      "name": "Siemens Energy AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 152.0,
      "currency": "EUR",
      "market_cap": 130012315648,
      "pe_ratio": 95.0,
      "forward_pe": 28.98324,
      "roe": 16.816,
      "dividend_yield": 46.0,
      "momentum_6m": 58.33333333333333,
      "momentum_12m": 166.19965685093595,
      "rsi_14": 71.95574684426185,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 23,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/ENR.DE",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Analyst upgrades and company guidance point to sustained momentum from record orders, revenue growth matching or exceeding industry at 12% annually, and structural tailwinds in grids/energy transition. Expansions in the U.S. bolster execution confidence, outweighing elevated valuations given technical strength above key moving averages and positive broker outlooks targeting \u20ac164-170.[1][3][4]",
      "company_overview": "Siemens Energy AG is a Germany-based energy technology company focused on power generation, grids, and energy-transition projects, with a strong market position driven by record order intake and double-digit revenue growth. The stock has surged dramatically, from below \u20ac30 in mid-2024 to around \u20ac143-152 recently, reflecting improved fundamentals amid grid infrastructure and energy-transition demand.[1][2] It now trades at a high P/E of 95.0 and P/S of 3.4x, elevated versus industry peers, supported by 13% recent revenue growth and forecasts of 12% annually through 2029.[1][2]",
      "key_developments": [
        "Deutsche Bank raised its price target to \u20ac170 from \u20ac135 (Jan 29, 2026), citing stronger order pipeline, profitability, and grid/energy-transition demand; Jefferies lifted to \u20ac164 from \u20ac134 (Feb 2, 2026) on improved earnings visibility.[1]",
        "Company forecasts 11-13% comparable revenue growth and 9-11% profit margin for FY2026, trending toward upper end of guidance after strong Q4; early exit from federal guarantee enables earlier dividend payment.[3]",
        "Announced $421M expansion in North Carolina (Feb 3, 2026) and Alabama production expansion as part of $1B investment, signaling U.S. growth commitment.[4]",
        "Shares gained 26% in the past month (as of early Feb 2026), extending 186% annual return, though P/S premium raises valuation concerns versus industry.[2]"
      ],
      "catalysts": [
        "Q1 FY2026 earnings and guidance confirmation, potentially affirming upper-end trends and dividend details.[3]",
        "Further U.S. expansion milestones, including North Carolina/Alabama project progress amid global energy demand.[4]",
        "Broker target follow-through or additional upgrades on order backlog visibility.[1]"
      ],
      "risk_factors": [
        "Elevated P/S (3.4x vs. industry <1.7x) and P/E (95x) leave room for pullback if revenue growth disappoints or macro sentiment shifts.[1][2]",
        "Legacy onshore wind challenges, project execution risks, and potential delays in energy-transition spending.[1]"
      ],
      "sources": [
        "https://capital.com/en-int/analysis/siemens-energy-stock-forecast",
        "https://simplywall.st/stocks/de/capital-goods/etr-enr/siemens-energy-shares/news/siemens-energy-ags-etrenr-26-price-boost-is-out-of-tune-with",
        "https://www.siemens-energy.com/global/en/home/investor-relations.html",
        "https://www.perplexity.ai/finance/ENR.DE"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "SAF",
      "name": "Safran SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 308.0,
      "currency": "EUR",
      "market_cap": 128284680192,
      "pe_ratio": 29.758453,
      "forward_pe": 29.628347,
      "roe": 34.745997,
      "dividend_yield": 94.0,
      "momentum_6m": 5.987609611503686,
      "momentum_12m": 26.409959646058656,
      "rsi_14": 39.782594994443805,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 20,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/SAF.PA",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Safran's dominant position in commercial aero engines and high ROE/ROIC (27.93%/18.25%) support outperformance versus peers like RTX/GE, underpinned by Morningstar's \u20ac391 fair value (vs. ~\u20ac300 current, implying 30%+ upside).[1][2] Recent all-time highs and 45%+ yearly gains reflect sustained demand in global aviation recovery, though elevated P/E and short-term forecasts suggest tempered near-term gains.[1][2]",
      "company_overview": "Safran SA is a leading French aerospace and defense company specializing in aircraft engines, equipment, and propulsion systems, holding a strong market position as a key supplier to Airbus and Boeing with robust financials including \u20ac7.85B in sales revenues, \u20ac5.05B net income, and a market cap of \u20ac126.23B.[1][2] The stock has shown solid performance, trading around \u20ac305 recently with a 45.52% yearly gain as of late October 2025, though it dipped to \u20ac298.25 as its lowest since January 2026 amid broader industrials sector dynamics.[1][3] Key metrics reflect high quality (ROE 34.7%, normalized ROE 27.93%) but elevated valuations (P/E 29.8 trailing, 38.74 normalized).[1][2]",
      "key_developments": [
        "Stock reached multiple all-time highs in late 2025 (e.g., \u20ac305.80 on 2025-10-03, \u20ac298.80 on 2025-09-30), with 8.83% gain over prior 4 weeks as of early October 2025, signaling strong momentum amid aerospace recovery.[1]",
        "Recent trading volatility in early February 2026, with prices fluctuating between \u20ac251.50-\u20ac305.40 (e.g., \u20ac302.50 close on Feb 05, \u20ac300.70 on Feb 04), down from peaks but up 0.56% daily to \u20ac305.30 as of Oct 28 data point.[1][3]",
        "No major company-specific news in last 30 days (early Jan to Feb 07, 2026); performance driven by market trends, with Q4 forecast at \u20ac296.34 and 1-year at \u20ac273.15 per macro models.[1]"
      ],
      "catalysts": [
        "Q4 2026 earnings and guidance, potentially confirming engine backlog growth amid Airbus/Boeing ramp-ups.[1][5]",
        "Aerospace sector tailwinds from rising air travel and defense spending in Europe/US, with potential contract wins.[2]"
      ],
      "risk_factors": [
        "Valuation premium (38.74 P/E normalized, 546% above Morningstar fair value adjustment) vulnerable to aerospace supply chain disruptions or economic slowdowns.[1][2]",
        "Downward price forecasts (\u20ac296 Q4, \u20ac273 1-year) and recent volatility signal macro risks like EU industrials weakness (EU50/EU600 flat/mixed).[1][3]"
      ],
      "sources": [
        "https://tradingeconomics.com/saf:fp",
        "https://www.morningstar.com/stocks/xpar/saf/quote",
        "https://www.investing.com/equities/safran-historical-data",
        "https://www.safran-group.com/finance/safran-share-price",
        "https://www.safran-group.com/finance/glance",
        "https://finbox.com/ENXTPA:SAF/"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "GSK",
      "name": "GSK plc",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 2198.0,
      "currency": "GBP",
      "market_cap": 88211988480,
      "pe_ratio": 15.812949,
      "forward_pe": 11.246936,
      "roe": 43.310001,
      "dividend_yield": 328.0,
      "momentum_6m": 56.58391015225654,
      "momentum_12m": 50.047182405412705,
      "rsi_14": 85.63432835820896,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 19,
        "momentum": 23,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/GSK.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "GSK's strong 2025 execution in Specialty Medicines, beat on Q4 estimates, and reaffirmed long-term 2031 sales target of >\u00a340 billion underpin steady growth amid robust ROE (43.3%) and attractive P/E (15.8).[1][2][4] 2026 guidance signals mid-single-digit sales and high-single-digit core profit/EPS expansion, supported by pipeline momentum and dividend hikes, though tempered by segment declines and patent risks.[3][6] Recent +50-56% returns and alpha score (70/100, strong momentum/quality) suggest continued upside in a favorable healthcare backdrop, but valuation may limit explosive gains.",
      "company_overview": "GSK plc is a leading global healthcare company focused on pharmaceuticals, vaccines, and specialty medicines, with strong market positions in HIV, oncology, respiratory, immunology, and inflammation treatments.[1][2][4] In 2025, it delivered robust full-year performance, including 6-8% revenue growth to \u00a38.62 billion in Q4, core EPS up 12% to 172.0p, and core operating profit up 11% to \u00a39.783 billion, driven by double-digit growth in Specialty Medicines.[1][2][4] The stock has surged +56.6% over 6 months and +50% over 12 months, reflecting positive momentum amid a new CEO transition.[6]",
      "key_developments": [
        "Reported strong Q4 and FY 2025 results on February 4, 2026, with Q4 revenue up 6.2% to \u00a38.618 billion, core EPS up 10% to 25.5p, and profit before tax up to \u00a3950 million, beating estimates.[1][2][4]",
        "Issued 2026 guidance projecting turnover growth of 3-5%, core operating profit and core EPS growth of 7-9% at CER, with Specialty Medicines sales up low double-digits but Vaccines and General Medicines flat to low single-digit decline; reaffirmed 2031 sales >\u00a340 billion.[1][2][3][4][6]",
        "Declared increased FY 2025 dividend of 66p (Q4 at 18p) and 2026 dividend of 70p per share; shares rose ~4% post-earnings, topping \u00a320 for first time in over 20 years under new CEO Luke Miels.[1][6]",
        "Announced positive Phase III trial results in January 2026 for B-Well 1 and 2, supporting pipeline progress in immunology.[7]"
      ],
      "catalysts": [
        "Commercial launches and R&D acceleration in Oncology, Vaccines, and HIV, with 2026 as a key execution year per CEO.[1][2]",
        "Positive Phase III readouts like January 2026 B-Well trials and further pipeline advancements boosting Specialty Medicines growth.[7]",
        "Potential share price momentum from dividend yield appeal and analyst upgrades post-earnings."
      ],
      "risk_factors": [
        "Slower 2026 sales growth (3-5%) due to looming patent losses, Vaccines/General Medicines declines (low single-digit to flat), and rising R&D/SG&A costs.[2][3][6]",
        "Regulatory pressures, competitive dynamics in pharma, and moderate leverage (debt-to-equity 1.1, Altman Z-Score 2.13 grey zone).[3]"
      ],
      "sources": [
        "https://www.nasdaq.com/articles/gsk-q4-results-climb-sees-growth-fy26-backs-2031-sales-view-update",
        "https://www.zacks.com/stock/news/2828654/gsks-q4-earnings-sales-beat-estimates-stock-up-on-26-outlook",
        "https://www.gurufocus.com/news/8580044/gsk-projects-moderate-growth-in-turnover-and-earnings-by-2026",
        "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/",
        "https://www.ig.com/uk/news-and-trade-ideas/gsk-full-year-earnings--can-the-pharma-giant-deliver-on-post-dem-260203",
        "https://www.voxmarkets.com/articles/gsk-sees-slower-sales-growth-in-2026-as-patent-loss-looms-7c4f7f2",
        "https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "RIO",
      "name": "Rio Tinto Group",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Basic Materials",
      "price": 6843.0,
      "currency": "GBP",
      "market_cap": 111193030656,
      "pe_ratio": 14.716128,
      "forward_pe": 12.113603,
      "roe": 17.158002,
      "dividend_yield": 416.0,
      "momentum_6m": 49.673994048695945,
      "momentum_12m": 36.53139134072427,
      "rsi_14": 66.68874172185431,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 22,
        "momentum": 25,
        "catalyst": 0,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/RIO.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Rio Tinto's decision to stay independent preserves its strong standalone position in high-demand commodities like copper and iron ore, supported by undervaluation (19% DCF discount, low P/E vs. peers/industry) and solid financial metrics amid robust momentum (+49.7% 6m return).[1][2] Analysts like those at Deutsche Bank see optimistic prospects from organic copper expansion and strategic options in the critical minerals era, outweighing near-term merger disappointment.[3] Global energy transition demand bolsters its portfolio, with low beta (0.37) limiting volatility.[1]",
      "company_overview": "Rio Tinto Group is a leading global mining company with major assets in iron ore (Pilbara operations), copper (30% stake in Escondida and 66% in Oyu Tolgoi), and a market cap of approximately $151 billion, positioning it as a top player in the Metals & Mining sector.[1] The company maintains strong financial health, including a 25.39% operating margin, 19.2% net margin, current ratio of 1.53, debt-to-equity of 0.41, and Altman Z-Score of 3.67, despite a 3-year revenue growth rate of -3.9% and TTM revenue of $53.73 billion.[1] Its shares have delivered strong returns (11.6% over 30 days, 44.7% over 1 year per recent data), trading at a P/E of ~14.5x below industry averages, with DCF models indicating undervaluation by ~19% at \u00a366.76.[1][2]",
      "key_developments": [
        "Declined merger offer from Glencore to maintain independence, citing disagreements on leadership roles (retaining Chair and CEO), valuation, and ownership structure; talks ended by Feb 5, 2026 UK regulator deadline, leading to short-term share pullback (~1% drop).[1][3]",
        "Strong recent share performance with 5.3% return over 7 days and 11.6% over 30 days, though RSI at 71.35 signals overbought conditions; analysts divided post-merger abort, with some reinstating overweight ratings citing copper growth.[2][3]",
        "Robust profitability and balance sheet highlighted amid commodity price fluctuations; projected net income growth to $12.66B in 2026 (+16.61% YoY).[1][7]"
      ],
      "catalysts": [
        "2025 Annual Results release on February 19, 2026, potentially highlighting copper growth and financial performance.[5]",
        "2026 Final dividend ex-dividend date (TBD via calendar), supporting shareholder returns amid strong free cash flow projections (e.g., $13.6B by 2030).[2][4]",
        "Progress on organic copper production expansions at key assets like Oyu Tolgoi and Escondida.[1][3]"
      ],
      "risk_factors": [
        "Commodity price volatility and regulatory challenges in mining operations, amplified by \"age of critical minerals\" and resource nationalism.[1][3]",
        "Elevated valuation near 3-year P/E and P/S highs, with overbought RSI risking pullback; merger abort exposes standalone execution pressures.[1][2][3]"
      ],
      "sources": [
        "https://www.gurufocus.com/news/8586961/rio-tinto-rio-declines-offer-maintaining-independence",
        "https://simplywall.st/stocks/gb/materials/lse-rio/rio-tinto-group-shares/news/has-the-market-fully-reflected-rio-tinto-lserios-strong-rece",
        "https://www.morningstar.com/news/marketwatch/2026020614/whats-next-for-rio-tinto-and-glencore-after-260-billion-megamerger-aborted",
        "https://www.riotinto.com/en/invest/financial-calendar",
        "https://www.riotinto.com/en/invest/financial-news-performance",
        "https://www.riotinto.com/en/invest/reports",
        "https://eulerpool.com/en/stock/Rio-Tinto-Stock-GB0007188757/NetIncome"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "AMAT",
      "name": "Applied Materials, Inc.",
      "exchange": "US",
      "index": "NASDAQ_SELECT",
      "sector": "Technology",
      "price": 322.51,
      "currency": "USD",
      "market_cap": 255983124480,
      "pe_ratio": 37.15553,
      "forward_pe": 26.492924,
      "roe": 35.508,
      "dividend_yield": 56.99999999999999,
      "momentum_6m": 75.29524861161806,
      "momentum_12m": null,
      "rsi_14": 48.28819156800613,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 17,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AMAT",
      "signal": "BUY",
      "confidence": "MEDIUM",
      "reasoning": "AMAT benefits from AI-driven capex by major chipmakers like TSMC, supporting demand for its tools in data centers and advanced nodes, with recent EPS beats ($2.17 vs. $2.11) and upward analyst revisions signaling momentum.[1][3] Despite near-term revenue declines expected in Q1 FY2026, full-year guidance points to +1.27% EPS growth and +2.34% revenue growth, positioning it well in a semiconductor recovery.[2][4] Valuation appears reasonable relative to peers, though China export risks temper conviction.[3]",
      "company_overview": "Applied Materials, Inc. (AMAT) is a leading provider of manufacturing equipment, services, and software for the semiconductor, display, and related industries, holding a strong position in advanced chipmaking tools amid surging AI-driven demand.[1][3] The stock has delivered robust performance with a 6-month return of +75.3%, reaching $322.51 after a 6.1% surge on February 6, 2026, driven by analyst upgrades and solid fundamentals including ROE of 35.5% and recent EPS beats.[1] Its market cap stands at approximately $256 billion, with a \"Moderate Buy\" consensus and average price target of $315.15.[1]",
      "key_developments": [
        "Shares jumped 6.1% to $322.51 on February 6, 2026, on high volume (8.2M shares), following analyst upgrades including Deutsche Bank to $390 (buy), KeyCorp to $380 (overweight), and Morgan Stanley to $364 (overweight).[1]",
        "Stock closed at $318.67 after a -2.96% drop in a recent session, underperforming broader markets amid pre-earnings caution, though forward P/E of 34.41 remains below industry average.[4]",
        "Insider sale by a senior VP of shares worth $952,960 at $238.24 average price, reducing ownership by 4.53%; company declared $0.46 quarterly dividend (ex-date Feb 19, yield ~0.6%).[1]"
      ],
      "catalysts": [
        "Q1 FY2026 earnings on February 12, 2026, with consensus EPS $2.19 and revenue $6.89B; potential beat could drive further upside given history of surprises.[2]",
        "AI-related demand acceleration and customer capex ramps in advanced packaging and next-gen chips.[3]"
      ],
      "risk_factors": [
        "Year-over-year earnings decline expected (-8% EPS, -3.9% revenue) in upcoming quarter, with potential miss amplifying volatility.[2]",
        "U.S.-China export restrictions on high-end equipment, delaying orders and shipments to impact revenue visibility.[3]"
      ],
      "sources": [
        "https://www.marketbeat.com/instant-alerts/applied-materials-nasdaqamat-trading-up-61-whats-next-2026-02-06/",
        "https://www.nasdaq.com/articles/applied-materials-amat-expected-beat-earnings-estimates-can-stock-move-higher",
        "https://simplywall.st/stocks/us/semiconductors/nasdaq-amat/applied-materials/news/applied-materials-balances-ai-growth-opportunity-with-new-ch",
        "https://www.zacks.com/stock/news/2828386/heres-why-applied-materials-amat-fell-more-than-broader-market",
        "https://www.tipranks.com/news/applied-materials-stock-amat-plunges-despite-hopes-for-a-more-constructive-direction"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "DHL",
      "name": "Deutsche Post AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 49.7,
      "currency": "EUR",
      "market_cap": 57314856960,
      "pe_ratio": 16.188925,
      "forward_pe": 15.037458,
      "roe": 16.792,
      "dividend_yield": 372.0,
      "momentum_6m": 21.72421879525457,
      "momentum_12m": 48.088536973267004,
      "rsi_14": 73.08786675989094,
      "alpha_score": 69,
      "score_breakdown": {
        "value": 18,
        "quality": 16,
        "momentum": 23,
        "catalyst": 5,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/DHL.DE",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "DHL Group's resilient profitability, exceptional FCF generation (\u20ac2.3 billion ex-M&A over 9M 2025), and unchanged FY2025 guidance (EBIT \u2265\u20ac6 billion, FCF ex-M&A ~\u20ac3 billion) underscore operational strength amid macro pressures.[1][2][3] Cost discipline, pricing power, and buybacks support earnings growth and shareholder value, aligning with 16.8% ROE and 69/100 Alpha Score (strong momentum/quality).[2][6] At 16.2 P/E and 49.7 price, valuation appears attractive for logistics leader with GDP+ potential.[5][6]",
      "company_overview": "Deutsche Post AG (DHL Group), the global logistics leader, operates diversified segments including DHL Express, Global Forwarding Freight, Supply Chain, and Post & Parcel Germany, delivering structural GDP+ growth and strong cash generation.[1][2][5] In Q3 2025 (ended September 30), revenue dipped 2.3% YoY to \u20ac20.1 billion due to currency effects and lower volumes, but EBIT rose 7.6-8% to \u20ac1.5 billion with a 7.3% margin, driven by cost management and pricing.[1][2][3] The stock has shown robust momentum with +48.1% 12m return, supported by 66.6% YoY free cash flow growth to \u20ac1.2 billion (ex-M&A).[2][3]",
      "key_developments": [
        "Q3 2025 results (November 6): EBIT +7.6% to \u20ac1.477 billion, net profit +9.5% to \u20ac888 million, FCF ex-M&A +80.8% to \u20ac1.234 billion; shares +5.25% post-announcement despite revenue decline.[1][2][3]",
        "Division highlights: Post & Parcel Germany EBIT +27.3% to \u20ac218 million on parcel growth and pricing; DHL eCommerce EBIT doubled; Express +0.8% EBIT; Supply Chain +1.6% EBIT; Global Forwarding Freight -29.6% EBIT on volume headwinds.[1][2][3]",
        "Shareholder returns: Plans to cancel 50 million shares in November 2025; ongoing \u20ac6 billion buyback through 2026 end.[2]"
      ],
      "catalysts": [
        "Q4 2025 and FY2025 results (early March 2026): Seasonally strong year-end business could confirm guidance and drive upside.[1][3][6]",
        "Share buyback progression and 50 million share cancellation (November 2025 onward): Enhances EPS and supports multiple expansion.[2]",
        "Potential volume recovery in Express/Global Forwarding amid trade stabilization.[2][3]"
      ],
      "risk_factors": [
        "Persistent macro headwinds: Currency volatility, US route volume declines, and trade conflicts pressuring revenue (e.g., Global Forwarding -9.2% revenue).[1][2][3]",
        "Division-specific weakness: Ongoing letter volume decline in Post Germany and freight market softness could weigh on margins if cost controls falter.[1][3]"
      ],
      "sources": [
        "https://reporting-hub.group.dhl.com/ecomaXL/files/DHL-Group-Quarterly-Statement-Q3-2025.pdf",
        "https://www.investing.com/news/company-news/dhl-group-q3-2025-slides-ebit-rises-8-despite-revenue-dip-fcf-soars-67-93CH-4336852",
        "https://group.dhl.com/en/media-relations/press-releases/2025/dhl-group-financial-figures-q3-2025.html",
        "https://reporting-hub.group.dhl.com/2025-q3/en/business-performance/",
        "https://group.dhl.com/en/investors.html",
        "https://simplywall.st/stocks/de/transportation/etr-dhl/deutsche-post-shares/past",
        "https://group.dhl.com/en/investors/ir-download-center.html"
      ],
      "target_timeframe": "3-6 months"
    }
  ],
  "dashboard_stats": {
    "has_history": true,
    "total_predictions": 40,
    "timeframes": [
      "30d",
      "60d",
      "90d"
    ],
    "default_timeframe": "90d",
    "timeframe_stats": {
      "30d": {
        "evaluated": 0,
        "pending": 40,
        "correct": 0,
        "incorrect": 0,
        "inconclusive": 0,
        "win_rate": null,
        "per_signal": {
          "BUY": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "HOLD": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "AVOID": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          }
        }
      },
      "60d": {
        "evaluated": 0,
        "pending": 40,
        "correct": 0,
        "incorrect": 0,
        "inconclusive": 0,
        "win_rate": null,
        "per_signal": {
          "BUY": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "HOLD": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "AVOID": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          }
        }
      },
      "90d": {
        "evaluated": 0,
        "pending": 40,
        "correct": 0,
        "incorrect": 0,
        "inconclusive": 0,
        "win_rate": null,
        "per_signal": {
          "BUY": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "HOLD": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "AVOID": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          }
        }
      }
    },
    "evaluated": 0,
    "pending": 40,
    "correct": 0,
    "incorrect": 0,
    "inconclusive": 0,
    "win_rate": null,
    "per_signal": {
      "BUY": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      },
      "HOLD": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      },
      "AVOID": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      }
    },
    "streaks": {
      "GSK": 2,
      "DG": 1,
      "ENR": 2,
      "TKA": 2,
      "AMAT": 2,
      "SAF": 2,
      "EN": 2,
      "RIO": 2,
      "FERG": 2,
      "AZN": 2
    },
    "weight_overrides": {},
    "active_weights": {
      "value": 25,
      "quality": 25,
      "momentum": 25,
      "catalyst": 15,
      "liquidity": 10
    },
    "base_weights": {
      "value": 25,
      "quality": 25,
      "momentum": 25,
      "catalyst": 15,
      "liquidity": 10
    },
    "recent_evaluations": [],
    "performance_timeline": [
      {
        "date": "2026-02-07",
        "win_rate": null,
        "total_predictions": 20,
        "evaluated": 0,
        "correct": 0,
        "avg_return": null,
        "buy_accuracy": null,
        "hold_accuracy": null,
        "avoid_accuracy": null
      },
      {
        "date": "2026-02-08",
        "win_rate": null,
        "total_predictions": 40,
        "evaluated": 0,
        "correct": 0,
        "avg_return": null,
        "buy_accuracy": null,
        "hold_accuracy": null,
        "avoid_accuracy": null
      }
    ]
  }
}